The effect of using different contrast agents in CT scan on radiation dose during radiotherapy

Comparison of Radiation Dose Calculated by treatment planning System (TPS) of Radiation Therapy in CT Imaging of three Prostate Cancer Patients groups that have been Imaging with Three Different contrast agents Omnipaque, Visipaque and Ultravist

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190814044528N1

Enrollment

Registered

2020-02-02

Start date

2020-04-03

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer. Malignant neoplasm of prostate

Interventions

Intervention 1: First Intervention group: prostate cancer Patients whose CT imaging done with intravenous injection of Visipaque contrast agent and it will be given a standard injection of 1 ml per

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Prostate cancer patients who are referred to the CT scan ward for CT imaging and don't have the exclusion criteria

Exclusion criteria

Exclusion criteria: Patients under 18 years old Patients with kidney problems Diabetic patients Patients with a history of asthma and immunological allergies People who had allergy to the use of contrast agents in the past

Design outcomes

Primary

Measure	Time frame
Radiation dose of the patient. Timepoint: After CT imaging with injection of contrast material. Method of measurement: Radiotherapy treatment planning software (TPS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Reshadatian

Ahvaz University of Medical Sciences

m.reshadatian@gmail.com+98 61 3333 3477

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026